Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Enzalutamide

FDA-approved product (capsule, oral), marketed as Enzalutamide, Xtandi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Enzalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma
  • Prostate neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Enzalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Enzalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

    NCT03344211 · start 2018-11-21

    Registered record
    Registry ID
    NCT03344211
    Conditions
    Castration-Resistant Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer
    Interventions
    Enzalutamide; Laboratory Biomarker Analysis; Radium Ra 223 Dichloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-11-21
    Completion
    2027-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer
    InterventionEnzalutamide; Laboratory Biomarker Analysis; Radium Ra 223 Dichloride
    PhasePhase 2
    Registry statusActive not recruiting

  • Study to Evaluate CCS1477 in Advanced Tumours

    NCT03568656 · start 2018-07-23

    Registered record
    Registry ID
    NCT03568656
    Conditions
    Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors
    Interventions
    CCS1477; Abiraterone acetate; Enzalutamide; Darolutamide; Olaparib; Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-07-23
    Completion
    2025-07-06
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors
    InterventionCCS1477; Abiraterone acetate; Enzalutamide; Darolutamide +2 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

    NCT03148795 · start 2017-07-04

    Registered record
    Registry ID
    NCT03148795
    Conditions
    Prostate Cancer
    Interventions
    Talazoparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-04
    Completion
    2023-03-31
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTalazoparib
    PhasePhase 2
    Registry statusCompleted

  • Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

    NCT03002220 · start 2016-12-21

    Registered record
    Registry ID
    NCT03002220
    Conditions
    Prostate Cancer
    Interventions
    radium-223
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-21
    Completion
    2021-06-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionradium-223
    PhasePhase 2
    Registry statusCompleted

  • Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

    NCT02601014 · start 2016-03-15

    Registered record
    Registry ID
    NCT02601014
    Conditions
    Prostate Cancer; Recurrent Prostate Carcinoma; Stage IV Prostate Adenocarcinoma
    Interventions
    Ipilimumab; Nivolumab; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-03-15
    Completion
    2021-10-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Recurrent Prostate Carcinoma; Stage IV Prostate Adenocarcinoma
    InterventionIpilimumab; Nivolumab; Enzalutamide
    PhasePhase 2
    Registry statusCompleted

  • Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

    NCT02566772 · start 2016-03

    Registered record
    Registry ID
    NCT02566772
    Conditions
    Metastatic Castration Resistant Prostate Cancer
    Interventions
    TAS3681
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03
    Completion
    2024-04-26
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Resistant Prostate Cancer
    InterventionTAS3681
    PhasePhase 1
    Registry statusCompleted

  • A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC

    NCT02669147 · start 2016-01-26

    Registered record
    Registry ID
    NCT02669147
    Conditions
    Castration Resistant Prostate Cancer (CRPC)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-01-26
    Completion
    2021-03
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Resistant Prostate Cancer (CRPC)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

    NCT02384382 · start 2015-11-30

    Registered record
    Registry ID
    NCT02384382
    Conditions
    Prostate Carcinoma Metastatic to the Bone; Castration Resistant Prostate Cancer
    Interventions
    Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-11-30
    Completion
    2019-05-03
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Carcinoma Metastatic to the Bone; Castration Resistant Prostate Cancer
    InterventionEnzalutamide
    PhasePhase 2
    Registry statusCompleted

  • Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

    NCT02491411 · start 2015-09

    Registered record
    Registry ID
    NCT02491411
    Conditions
    Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer
    Interventions
    Dexamethasone; Enzalutamide; Laboratory Biomarker Analysis; Quality-of-Life Assessment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2018-03
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer
    InterventionDexamethasone; Enzalutamide; Laboratory Biomarker Analysis; Quality-of-Life Assessment
    PhaseNot applicable
    Registry statusTerminated

  • EXTEND Exercise Trial

    NCT02256111 · start 2015-05-13

    Registered record
    Registry ID
    NCT02256111
    Conditions
    Non-metastatic, Hormone naïve Prostate Cancer
    Interventions
    Enzalutamide; Androgen deprivation therapy; Supervised exercise training
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05-13
    Completion
    2018-07-17
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-metastatic, Hormone naïve Prostate Cancer
    InterventionEnzalutamide; Androgen deprivation therapy; Supervised exercise training
    PhasePhase 2
    Registry statusCompleted

  • Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

    NCT02215096 · start 2014-11-13

    Registered record
    Registry ID
    NCT02215096
    Conditions
    Neoplasms
    Interventions
    GSK2636771; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-11-13
    Completion
    2019-10-03
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionGSK2636771; Enzalutamide
    PhasePhase 1
    Registry statusCompleted

  • Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

    NCT02254785 · start 2014-10

    Registered record
    Registry ID
    NCT02254785
    Conditions
    Metastatic Castration-Resistant Prostatic Cancer
    Interventions
    cabazitaxel; Abiraterone; Enzalutamide 160mg daily (oral)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-10
    Completion
    2020-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostatic Cancer
    Interventioncabazitaxel; Abiraterone; Enzalutamide 160mg daily (oral)
    PhasePhase 2
    Registry statusUnknown

  • Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

    NCT02215161 · start 2014-09-02

    Registered record
    Registry ID
    NCT02215161
    Conditions
    Castration Levels of Testosterone; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7
    Interventions
    Selinexor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-09-02
    Completion
    2018-04-02
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone +2 more
    InterventionSelinexor
    PhasePhase 2
    Registry statusTerminated

  • An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

    NCT02294461 · start 2014-04-23

    Registered record
    Registry ID
    NCT02294461
    Conditions
    Progressive Metastatic Prostate Cancer
    Interventions
    Enzalutamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-04-23
    Completion
    2024-07-17
    Enrolment
    395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Metastatic Prostate Cancer
    InterventionEnzalutamide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

    NCT02446405 · start 2014-03

    Registered record
    Registry ID
    NCT02446405
    Conditions
    Prostatic Neoplasms
    Interventions
    Enzalutamide; NSAA; LHRHA or Surgical Castration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2014-03
    Completion
    2027-06-30
    Enrolment
    1,125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionEnzalutamide; NSAA; LHRHA or Surgical Castration
    PhasePhase 3
    Registry statusActive not recruiting